ClinicalTrials.gg
CompletedNCT04227977VOID-HFUpdated Oct 25, 2023

Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)

An interventional study of JuxtaFlow System in Cardiorenal Syndrome, sponsored by 3ive Labs. Completed at 4 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by 3ive Labs · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cardio-Renal Syndrome with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Cardio-Renal Syndrome · United States.

Enrollment
13th of 16
8 · median 20
Started
2020
the only one that year
No phase
6 of 18
3 open now
Registered
14th of 18
by date
Lead sponsor
1 of 18
3ive Labs

Among the 18 studies in Cardio-Renal Syndrome with a site in United States, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 6 with no phase, and was the 14th registered.

Cardio-Renal Syndrome

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

Browse Cardio-Renal Syndrome studies →

Open to participants now

3 of the 18 studies in Cardio-Renal Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Cardio-Renal Syndrome studies recruiting now, 9 (75%) set no upper age limit and 2 (17%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cardio-Renal Syndrome with a site in United States, or all of them as a file.
02

Study summary

The Cardiorenal Syndrome during Acute decompensated heart failure (ADHF) with persistent congestion despite high dose IV diuretic therapy is associated with remarkable morbidity, which can include the need for renal dialysis or ultrafiltration, an increased length of stay, and high mortality rates. The aims and purpose of this feasibility clinical research trial are: 1. to evaluate the safety profiles associated with performing negative pressure diuresis for the treatment of hypervolemia associated with the cardiorenal syndrome during ADHF with persistent congestion despite high dose IV diuretic therapy via the investigational JuxtaFlow® System, and 2. to evaluate the effectiveness of the investigational JuxtaFlow System in treatment of hypervolemia associated with ADHF.

Read the detailed description

The Cardiorenal Syndrome during Acute decompensated heart failure (ADHF) with persistent congestion despite high dose IV diuretic therapy is associated with remarkable morbidity, which can include the need for renal dialysis or ultrafiltration, an increased length of stay, and high mortality rates. The primary renal adjuvant therapies for presistent congestion despite high dose IV diuretic therapy are ultrafiltration and dialysis. Unfortunately, clinical decongestion is uncommon in this population despite aggressive therapies. Negative pressure diuresis in the renal pelvis has the potential to treat hypervolemia associated with ADHF by increasing renal filtration and increased urine output.

Primary endpoint: The characterization of the type, frequency, severity, and device-relatedness of adverse events (AEs) associated with the placement, use, and removal of the JuxtaFlow System and a 28-day post-treatment actuarial follow up.

Secondary endpoints: a) Increase in urine output from baseline to discontinuation of treatment with the JuxtaFlow System. b) Reduction of congestion (as measured by change in BNP) during the course of the treatment with the JuxtaFlow System. c) The relative change in creatinine clearance from baseline to treatment period after 24 hours of treatment or until discontinuation of the investigational treatment using each study subject as their own control. The change in creatinine clearance from the baseline period to the 24 hour post End of Treatment (EOT) period.

03

Conditions studied

  • Cardiorenal Syndrome

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥22 years of age
  2. Patients admitted with primary diagnosis of ADHF
  3. Persistent volume overload with venous congestion despite at least 24 hours of IV diuretic therapy, including either a single bolus ≥ 100 mg or continuous drip ≥ 10 mg/hour of furosemide equivalent, where:

    1. Volume overload defined by the presence of pulmonary edema, 2+ peripheral edema, or orthopnea
    2. Venous congestion defined by at least one of the following:

    i. Jugular venous pressure > 10 cm on physical exam ii. Central venous pressure > 10 mmHg iii. Pulmonary capillary wedge pressure > 22 mmHg c) Evidence of low natriuretic response to high dose diuretic therapy defined by spot urine sodium \< 70 mmol

  4. Ability to have the JuxtaFlow® System catheters placed at bedside
  5. Anticipated to have an inpatient hospital admission that is ≥ 72 hours
  6. Patients that are willing and able to provide for this research trial, or if the patient is not able to provide consent due to their clinical condition, a legal guardian, spouse, or next of kin to the patient with medical power of attorney that is willing to provide consent for the patient's participation in this research trial
  7. Patients who agree to comply with the study procedures and specified evaluations

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or nursing mothers
  2. Creatinine > 3.0 mg/dL at admission to the hospital
  3. Systolic blood pressure \< 100 mmHg at the time of enrollment
  4. Clinical instability likely to require the addition of intravenous vasoactive drugs, vasodilators and/or inotropic agents.
  5. Alternative explanation for the renal impairment causing the persistent volume overload, such as obstructive nephropathy, contrast induced nephropathy, or acute tubular necrosis
  6. Any patient with an \< 15 ml/min or prior diagnosis of CKD 5
  7. Any patient presenting with hematuria as defined by urine dipstick reading of > 1+ blood
  8. Any patient presenting with proteinuria as defined by urine dipstick reading of > 3+ protein.
  9. Any patient that would not potentially benefit from this therapy in the opinion of the investigator
  10. Any patient with a current upper or lower urinary tract infection (tested during pre-screening)
  11. Any patient with a of the upper urinary tract
  12. Any patient who are currently experiencing unexplained/unexpected proteinuria as determined by the investigator
  13. Any patient with a current unrepaired ureteral avulsion as determined by the investigator
  14. Any patient that would require an MRI between enrollment and completion of the post-treatment baseline period
  15. Any secondary condition as determined by the investigator that would place the subject at an increased risk, or preclude the subject's full compliance with the study procedures, including injuries to the urinary organs and/or external genitals
  16. Any use of an iodinated radiocontrast material in the past 72 hours prior to study enrollment or anticipated use of intravenous contrast during the current hospitalization.
  17. Pre-enrollment ultrasound revealing any of the following:

    1. Congenital abnormality in either kidney
    2. Only one kidney
    3. Presence of debris, stones or an obstruction in the renal pelvis, ureter or urinary tract
  18. Current or planned treatment with an drug (IND), device (IDE), or other investigational intervention within 3 months prior to or during participation in this clinical trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treatment

    JuxtaFlow

    Device: JuxtaFlow System

Interventions

  • DeviceJuxtaFlow System

    The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.

06

What researchers measure

Primary outcomes

  1. Device related adverse events

    The characterization of the type, frequency, severity, and device-relatedness of adverse events (AEs) associated with the placement, use, and removal of the JuxtaFlow System and a 28-day post-treatment follow up.

    Time frame: 28 days

Secondary outcomes

  1. Urine output

    The change in urine output from baseline to discontinuation

    Time frame: 24 hours

  2. Congestion

    The change in congestion (as measured by change in BNP) during the course of treatment

    Time frame: 24 hours

  3. Creatinine Clearance

    The change in creatinine clearance from baseline to discontinuation

    Time frame: 24 hours

07

Study locations

4 sites
  • University of Florida
    Gainesville, Florida 32611, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Univ. of Texas Health
    San Antonio, Texas 78229, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in May 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2020
First posted
Jan 14, 2020
StartActual
Jun 12, 2020
Primary completionActual
May 1, 2023
CompletionActual
Oct 20, 2023
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04227977
Lead sponsor
3ive Labs
Responsible party
Sponsor
First posted
Jan 14, 2020
Start date
Jun 12, 2020
Primary completion
May 1, 2023
Completion
Oct 20, 2023
Last update
Oct 25, 2023

Study contacts

Wilson Tang, MD
principal investigator · The Cleveland Clinic
Alex Parker, MD
principal investigator · Univ. of Florida, Gainesville
Wayne Old, MD
principal investigator · Sentara Norfolk General Hospital
Shweta Bansal, MD
principal investigator · Univ. of Texas Health, San Antonio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion